The stock of Adamis Pharmaceuticals Corp (NASDAQ:ADMP) is a huge mover today! About 95,131 shares traded hands. Adamis Pharmaceuticals Corp (NASDAQ:ADMP) has declined 57.78% since April 5, 2016 and is downtrending. It has underperformed by 59.74% the S&P500.
The move comes after 9 months positive chart setup for the $56.76M company. It was reported on Nov, 7 by Barchart.com. We have $5.89 PT which if reached, will make NASDAQ:ADMP worth $65.27M more.
Analysts await Adamis Pharmaceuticals Corp (NASDAQ:ADMP) to report earnings on November, 14.
According to Zacks Investment Research, “Adamis Pharmaceuticals Corporation, formerly Cellegy Pharmaceuticals, Inc., is a specialty pharmaceutical company engaged engages in the research, development, and commercialization of prescription medicines for the treatment of viral infections. Adamis Pharmaceuticals is composed of two wholly owned subsidiaries, Adamis Labs and Adamis Viral Therapies. Adamis Labs is a commercial stage specialty pharmaceutical company targeting high-prescribing physicians in the allergy, respiratory and pediatric medicine market segments. To complement and add to the sales efforts of Adamis Labs, Adamis Viral Therapies is focused on the development of patented, highly-valued proprietary vaccine technology that Adamis believes has the potential to prevent or treat infections such as influenza or chronic hepatitis. Adamis also provides packaging for pharmaceutical and nutraceutical products. The company is headquartered in Del Mar, California.”
More news for Adamis Pharmaceuticals Corp (NASDAQ:ADMP) were recently published by: Marketwatch.com, which released: “Virtual Stock Exchange” on April 25, 2011. Medgadget.com‘s article titled: “Adamis Pharmaceuticals Corporation Clinical Trial Review, Industry Analysis …” and published on November 07, 2016 is yet another important article.
ADMP Company Profile
Adamis Pharmaceuticals Corporation, incorporated on April 22, 2004, is a pharmaceutical company. The Firm is engaged in the development of its specialty pharmaceutical products. The Firm is developing various products in the allergy and respiratory markets, including a dry powder inhaler technology that it acquired from 3M Company (3M). The Company’s product portfolio includes specialty pharmaceutical products, such as Epinephrine pre-filled syringe (PFS), APC-5000 dry powder inhaler (DPI), APC-1000 and APC-2000, and biotechnology products, such as TeloB-VAX (vaccine), APC-100, APC-200 and APC-300.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.